Khan Nedd, MD
Internal Medicine · Grand Rapids, MINPI 1043284219
Payments from drug & device makers
Across 569 payments — averaging $3916.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$762K
- Chiesi USA, Inc.$611K
- Takeda Pharmaceuticals U.S.A., Inc.$481K
- Viiv Healthcare Company$100K
- Sanofi US Services Inc.$76K
- Pfizer$49K
- plus $150K from 25 others
Across 3 payments — averaging $2698.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 3 | $762,240 |
| Chiesi USA, Inc. | 283 | $611,245 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $481,004 |
| Viiv Healthcare Company | 81 | $100,248 |
| Sanofi US Services Inc. | 23 | $75,588 |
| Pfizer | 30 | $48,651 |
| Amicus Therapeutics, Inc. | 14 | $38,851 |
| Sanofi | 14 | $32,503 |
| Amgen(2 entities) | 9 | $28,843 |
| Janssen Research & Development, LLC | 2 | $20,635 |
| E.r. Squibb & Sons, L.L.C. | 11 | $17,772 |
| Eli Lilly | 3 | $7,775 |
| Biogen | 9 | $1,107 |
| GSK | 24 | $549 |
| Johnson & Johnson(2 entities) | 12 | $345 |
| Genentech USA, Inc. | 8 | $225 |
| Merck | 4 | $221 |
| Gilead | 1 | $134 |
| Grifols USA, LLC | 5 | $100 |
| Novartis | 5 | $99 |
| Sanofi-aventis U.S. LLC | 2 | $94 |
| AstraZeneca(2 entities) | 5 | $85 |
| Argenx US, Inc. | 1 | $56 |
| US Oncology Corporate, Inc. | 1 | $36 |
| Alkermes, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
| Mckesson Specialty Care Distribution, LLC | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
How this compares
$2,228,541 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Grand Rapids
- Leslie PelkeyGrand Rapids$8.5M
- Robert SelfeGrand Rapids$238K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.